secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001213900-24-017520
Event type: earnings
Sentiment:  negative
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell FY2023 net loss widens to $5.8M; Q4 sales up 30% but margin pressured
------------------------------------------------------------------------------

- Net loss $5.8M ($0.75 per share) in FY2023 vs $2.5M ($0.32) prior year.
- Product sales $17.5M in FY2023, down 6% from $18.6M; Q4 sales $5.1M, up 30%.
- Gross margin fell to 22% in FY2023 from 41% due to contamination events and write-offs.
- EBITDA turned negative to ($2.6M) vs positive $350K in FY2022.
- Cash dropped to <$1M from $5.8M; FDA response on Re-Tain expected by May 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/0001213900-24-017520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390024017520/ea0200797-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-017520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer